Figure 4.

Topical LXA₄ attenuates inflammatory neovascularization and inhibition of its biosynthetic pathway exacerbates pathological angiogenesis. A: Heme-angiogenesis in corneas with 7 days of chronic injury was assessed by immunohistochemistry using CD31 as a specific endothelial antigen. Corneas from 12/15-LOX KO or matched congenic wild-type (wt) mice treated with or without topical LXA₄ (100 ng, t.i.d., 7 days) were collected and incubated in PBS containing fluorescein isothiocyanate-conjugated CD31/PECAM-1 monoclonal antibody and analyzed using a Zeiss Axiophot laser scanning confocal microscope. Images show neovascularization of representative corneal quadrants. All CD31⁺ vessels were traced manually and are expressed as total pixels (Image Pro Express 6.0) (n = 3 to 4; *P < 0.05). B: Topical 15-HETE exacerbates inflammatory neovascularization. Injured corneas were treated topically with either 15S-HETE (100 ng, t.i.d.) or sterile saline for 7 days. Images show representative whole corneal flat mounts (left panel, saline treatment alone; right panel 15S-HETE treatment). All CD31⁺ vessels were traced manually and are expressed as total pixels (n = 4; *P < 0.05).